BioLife Solutions, Inc. (NASDAQ:BLFS) Stock Holdings Decreased by Meros Investment Management LP

Meros Investment Management LP reduced its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 56.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 173,910 shares of the medical equipment provider's stock after selling 225,893 shares during the quarter. BioLife Solutions makes up 2.0% of Meros Investment Management LP's portfolio, making the stock its 23rd biggest holding. Meros Investment Management LP owned approximately 0.37% of BioLife Solutions worth $4,355,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in BLFS. Sequoia Financial Advisors LLC purchased a new position in shares of BioLife Solutions during the 2nd quarter worth about $466,000. Isthmus Partners LLC raised its stake in BioLife Solutions by 34.4% during the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 42,265 shares during the period. Mutual of America Capital Management LLC acquired a new position in shares of BioLife Solutions in the 2nd quarter valued at $8,592,000. Envestnet Asset Management Inc. grew its stake in shares of BioLife Solutions by 261.5% during the 2nd quarter. Envestnet Asset Management Inc. now owns 127,215 shares of the medical equipment provider's stock valued at $2,726,000 after buying an additional 92,021 shares during the period. Finally, Legato Capital Management LLC acquired a new stake in shares of BioLife Solutions during the 2nd quarter worth $233,000. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, CRO Garrie Richardson sold 3,070 shares of the business's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the transaction, the executive now owns 114,773 shares in the company, valued at $2,883,097.76. The trade was a 2.61 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Aby J. Mathew sold 17,604 shares of the firm's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $20.05, for a total value of $352,960.20. Following the sale, the executive vice president now owns 284,442 shares of the company's stock, valued at $5,703,062.10. This represents a 5.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,313 shares of company stock valued at $1,572,899. Corporate insiders own 2.20% of the company's stock.

BioLife Solutions Stock Up 0.5 %

Shares of NASDAQ:BLFS traded up $0.12 during mid-day trading on Wednesday, hitting $26.32. 151,049 shares of the company traded hands, compared to its average volume of 384,304. The firm has a market cap of $1.22 billion, a P/E ratio of -24.72 and a beta of 1.91. BioLife Solutions, Inc. has a 52-week low of $12.45 and a 52-week high of $28.88. The firm's 50 day simple moving average is $24.49 and its 200 day simple moving average is $23.47. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

Analysts Set New Price Targets

BLFS has been the subject of a number of research reports. HC Wainwright lowered their price target on BioLife Solutions from $29.00 to $27.00 and set a "buy" rating for the company in a research report on Monday, November 18th. TD Cowen boosted their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Finally, Craig Hallum increased their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat.com, BioLife Solutions currently has an average rating of "Moderate Buy" and a consensus price target of $27.50.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.